Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record.

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

Open access
Vrooman, Lynda M., Supko, Jeffrey G., Neuberg, Donna S., Asselin, Barbara L., Athale, Uma H., Clavell, Luis, Kelly, Kara M., Laverdière, Caroline, Michon, Bruno, Schorin, Marshall, Cohen, Harvey J., Sallan, Stephen E., Silverman, Lewis B. · 2010 · Pediatric Blood & Cancer

Abstract

Background: Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia (ALL); however, hypersensitivity develops in up to 30% of patients. We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase‐allergic patients. Patients and Methods: Between 2000 and 2002, 215 children with newly diagnosed ALL were enrolled on Dana‐Farber Cancer Institute ALL Consortium Protocol 00‐01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase. If E. coli asparaginase allergy developed, patients were switched to twice‐weekly intramuscular Erwinia asparaginase (25,000 IU/m 2). Nadir serum asparaginase activity (NSAA) was measured every 3 weeks. Results: Forty‐two patients (20%) developed E. coli asparaginase allergy and switched to Erwinia. Of 38 patients with evaluable samples, 34 (89%) Erwinia‐treated patients had at least one therapeutic NSAA (≥0.1 IU/ml). The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose. Associated toxicities included allergy in 14 (33%) and pancreatitis in 3 patients (7%). At a median follow‐up of 5.4 years, event‐free survival (±standard error) of the 42 patients who switched to Erwinia was 86 ± 5% compared with 81 ± 3% for the 170 patients without E. coli asparaginase allergy (P = 0.55). Conclusions: Twice‐weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase‐allergic patients. Development of E. coli allergy and subsequent treatment with twice‐weekly Erwinia did not adversely impact event‐free survival. Erwinia asparaginase should be considered for E. coli asparaginase‐allergic patients. Pediatr Blood Cancer 2010;54:199–205. © 2009 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.22225

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Vrooman, L. M., Supko, J. G., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L., Kelly, K. M., Laverdière, C., Michon, B., Schorin, M., Cohen, H. J., Sallan, S. E., & Silverman, L. B.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2009-08-11
Volume
54
Issue
2
Pages
199-205
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2060440673
Cited by
162
References
0
FWCI
8.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1002/pbc.22225
The paper
Vrooman, L. M., Supko, J. G., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L., Kelly, K. M., Laverdière, C., Michon, B., Schorin, M., Cohen, H. J., Sallan, S. E., & Silverman, L. B. (2010). Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.22225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.